Core Viewpoint - The company, Dongfang Risen, reported a decline in revenue and gross profit due to a mismatch in supply and demand in the photovoltaic market, but continues to pursue its "new energy, new materials" strategy to enhance competitiveness in various business areas [1]. Group 1: Financial Performance - In 2024, the company achieved operating revenue of 20.239 billion yuan and total assets of 43.094 billion yuan [1]. - The revenue and gross profit levels have decreased due to the impact of falling product prices in the photovoltaic industry [1]. Group 2: Industry Overview - The global photovoltaic industry is experiencing stable development despite macroeconomic adjustments, with a cumulative installed capacity of 1624 GW in 2023, representing over a 101-fold increase since 2008 [2]. - The market is primarily driven by long-term industrial capital, with competition shifting towards performance and technology [2]. Group 3: Global Expansion and Production Capacity - Dongfang Risen is focused on global expansion in new energy and new materials, with significant sales in photovoltaic modules, achieving 18.07 GW in 2024, including 6.79 GW in overseas sales [3]. - The company has established production bases in multiple locations, including China and Malaysia, and has branches in various international markets, creating a global marketing network [3]. Group 4: Technological Advancements - The company has achieved breakthroughs in heterojunction technology and has a strong patent portfolio with 878 authorized patents as of 2024 [4]. - The average production efficiency of heterojunction batteries has surpassed 26.2%, and the company has developed high-power modules with significant performance advantages [5][6]. Group 5: Strategic Response to Industry Challenges - In the short term, the photovoltaic industry is facing structural capacity mismatches, leading to a reshaping of the competitive landscape and stabilization of profitability for manufacturers [7]. - In the long term, the decline in industry prices is expected to lower installation costs and improve investment returns, with continued growth in downstream demand for photovoltaic installations [7].

Core Viewpoint - Haier Biomedical's overseas business is strategically positioned to mitigate the impact of U.S. tariffs, with a focus on localizing operations and enhancing product competitiveness in various international markets [2] Group 1: U.S. Market Impact - Haier Biomedical's revenue from the U.S. market accounted for less than 2% of total revenue in 2024, indicating limited exposure to U.S. tariffs [2] - The company has preemptively stocked up on orders before the tariff implementation, minimizing potential disruptions [2] - The firm emphasizes building internal capabilities to navigate complex international challenges through a "one country, one policy" approach [2] Group 2: Overseas Market Performance - In 2024, overseas revenue reached 715 million yuan, a year-on-year decline of 8.73%, but showed double-digit growth when excluding the impact of solar vaccine projects [2] - The company has seen a resurgence in order deliveries since Q3 2024, with Q4 showing positive growth, indicating recovery from previous disruptions [2] - The localization strategy has yielded results, with various product lines experiencing growth despite industry downturns, particularly in Europe and Asia-Pacific regions [2] Group 3: M&A Strategy and Performance - Haier Biomedical employs a "concentric circle" merger and acquisition strategy, targeting industry leaders with strong technological barriers and significant growth potential [2] - The integration of acquired businesses has shown significant results, with double-digit compound annual growth rates for the liquid nitrogen business and substantial revenue growth for other acquired units [2] Group 4: Financial Performance - In 2024, the company's gross margin was 47.99%, affected by changes in accounting policies, but would be 50.43% under consistent accounting standards [2] - The net profit for 2024 was 381 million yuan, influenced by non-operating factors such as investment income from equity disposals [2] - The decline in net profit was also attributed to the effects of ongoing M&A integrations and increased minority interests from subsidiary growth [2]